KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 70 filers reported holding KALA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.30 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,969,000 | +138.2% | 565,289 | 0.0% | 4.50% | +196.4% |
| Q4 2019 | $2,086,000 | -54.2% | 565,289 | -52.8% | 1.52% | -41.4% |
| Q3 2019 | $4,555,000 | -61.6% | 1,197,032 | -35.6% | 2.59% | -72.2% |
| Q2 2019 | $11,851,000 | -22.9% | 1,857,582 | 0.0% | 9.31% | -28.4% |
| Q1 2019 | $15,362,000 | +69.1% | 1,857,582 | 0.0% | 13.00% | +34.1% |
| Q4 2018 | $9,084,000 | -50.5% | 1,857,582 | 0.0% | 9.70% | +5.6% |
| Q3 2018 | $18,334,000 | -28.1% | 1,857,582 | 0.0% | 9.18% | -34.0% |
| Q2 2018 | $25,505,000 | -13.3% | 1,857,582 | 0.0% | 13.90% | -17.1% |
| Q1 2018 | $29,406,000 | -14.4% | 1,857,582 | 0.0% | 16.76% | -44.6% |
| Q4 2017 | $34,347,000 | -20.5% | 1,857,582 | -1.8% | 30.28% | -18.4% |
| Q3 2017 | $43,188,000 | – | 1,890,913 | – | 37.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |